



A novel *SCN5A* mutation, F1344S, identified in a patient with Brugada syndrome and fever-induced ventricular fibrillation

Dagmar I. Keller ^{a,b,1}, Hai Huang ^{c,1}, Juan Zhao ^c, Rudolf Frank ^d, Vivian Suarez ^b, Etienne Delacrétaiz ^e, Marijke Brink ^b, Stefan Osswald ^a, Nicola Schwick ^e, Mohamed Chahine ^{c,*}

^a Cardiology Department, University Hospital Basel, Switzerland

^b Cardiobiology Research Group, University Hospital Basel, Switzerland

^c Laval Hospital, Québec Heart Institute, Research Centre, 2725, Chemin Sainte-Foy, Sainte-Foy, Québec, Canada G1V 4G5

^d Cardiology Department, Tiefenau Hospital, Bern, Switzerland

^e Swiss Cardiovascular Center, Bern, Switzerland

Received 2 January 2006; received in revised form 3 February 2006; accepted 18 February 2006

Available online 3 March 2006

Time for primary review 14 days

Abstract

Objective: Brugada syndrome (BS) is an inherited electrical cardiac disorder characterized by right bundle branch block pattern and ST segment elevation in leads V1 to V3 on surface electrocardiogram that can potentially lead to malignant ventricular tachycardia and sudden cardiac death. About 20% of patients have mutations in the only so far identified gene, *SCN5A*, which encodes the α -subunit of the human cardiac voltage-dependent sodium channel (hNa_v1.5). Fever has been shown to unmask or trigger the BS phenotype, but the associated molecular and the biophysical mechanisms are still poorly understood. We report on the identification and biophysical characterization of a novel heterozygous missense mutation in *SCN5A*, F1344S, in a 42-year-old male patient showing the BS phenotype leading to ventricular fibrillation during fever.

Methods: The mutation was reproduced in vitro using site-directed mutagenesis and characterized using the patch clamp technique in the whole-cell configuration.

Results: The biophysical characterization of the channels carrying the F1344S mutation revealed a 10 mV mid-point shift of the *G/V* curve toward more positive voltages during activation. Raising the temperature to 40.5 °C further shifted the mid-point activation by 18 mV and significantly changed the slope factor in Na_v1.5/F1344S mutant channels from -6.49 to -10.27 mV.

Conclusions: Our findings indicate for the first time that the shift in activation and change in the slope factor at a higher temperature mimicking fever could reduce sodium currents' amplitude and trigger the manifestation of the BS phenotype.

© 2006 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.

Keywords: Brugada syndrome; Sudden cardiac death; Genetics; *SCN5A*; Sodium channel; Na_v1.5; Fever; Ventricular fibrillation

1. Introduction

The Brugada syndrome (BS) is an autosomic dominant inherited cardiac disorder without underlying structural

heart disease. The electrocardiographic (ECG) characteristics of the BS are a right bundle branch block pattern and ST segment elevation in leads V1 to V3 [1]. Clinically, the BS manifests by syncope and sudden cardiac death (SCD) from fast polymorphic ventricular tachycardia (VT) and ventricular fibrillation (VF). The diagnosis of the BS is based on this typical ECG pattern, either spontaneously manifesting or unmasked by sodium channel blockers [2–4]. The *SCN5A* gene is so far the only identified gene to be involved in genetically determined forms of BS and

* Corresponding author. Tel.: +1 418 656 8711x5447; fax: +1 418 656 4509.

E-mail address: mohamed.chahine@phc.ulaval.ca (M. Chahine).

¹ These authors contributed equally to this work.

mutations in the *SCN5A* gene have been identified in 10–30% of BS in genotyped families [5]. Recently a second locus on chromosome 3 has been identified [6]. Interestingly, this locus overlaps with the one of *SCN5A* and the involvement of *SCN5A* was excluded by a direct investigation. This suggests an important heterogeneity in the genetic background of the BS. The *SCN5A* gene encodes the α -subunit of the human cardiac voltage-dependent sodium channel, hNa_v1.5. This channel produces a depolarizing inward sodium current I_{Na} and subsequently inactivates within milliseconds. Mutations in *SCN5A* are associated with several cardiac electrical diseases among which the BS, the Long QT-Syndrome (LQTS) and Lenegre's disease are the best characterized. The mechanisms of how *SCN5A* mutations lead to different cardiac electrical diseases are still under investigation. In general, *SCN5A* mutations leading to the BS phenotype are associated with a loss of channel function with a reduction of the Na⁺ current [7–11]. Indeed, important qualitative alterations of the activation/inactivation mechanisms of the current may be involved. Clinically, the role of fever in unmasking the BS and triggering arrhythmias is of great importance [12–15]. However the underlying mechanisms remain unclear. Only few mutations leading to an exacerbation of the BS phenotype during fever have been studied functionally, and more data is needed to unravel and understand this important factor. The aim of this study was to investigate a family with the BS triggered by fever, to screen the *SCN5A* gene for mutations and to study the effects of the mutation on the channel function in an in vitro model.

2. Methods

2.1. Clinical evaluation

Subjects II-1 (index patient), III-1, III-2, III-3, III-4 underwent detailed clinical examinations including baseline 12-lead ECG and echocardiography. To unmask the Brugada ECG, subject II-1 received flecainide i.v. (2 mg/kg body weight) [5]. Subjects III-1, III-2, III-3 and III-4 did not undergo flecainide testing (declined by parents).

2.2. Molecular genetics

The study was performed according to the guidelines of the Declaration of Helsinki. Family members participating in the study gave written informed consent. Genomic DNA was extracted from peripheral lymphocytes. In the index patient, subject II-1, all coding exons of *SCN5A* were amplified by polymerase chain reaction (PCR) using primers designed in intronic flanking sequences according to the gene sequence described by Wang et al. [16]. The PCR products were directly sequenced using a big dye termination mix and analyzed by cycle sequencing using an automated laser fluorescent DNA sequencer (ABI Prism

377, Applied Biosystems, Foster City, CA, USA). In subjects III-1, III-2, III-3, and III-4, exon 23 was directly amplified by PCR and sequenced in both strands as described above.

2.3. Mutagenesis

Mutant hNa_v1.5/F1344S was generated using a Quick-Change™ site-directed mutagenesis kit according to the manufacturer's instructions (Stratagene, La Jolla, CA, USA), using the following nucleotide mutagenic sense and antisense primers:

```
5'-C GTC CTC CTC GTC TGC CTC ATC TCC TGG
CTC ATC TTC AGC ATC ATG G-3'
5'-CC ATT GAT GCT GAA GAT GAG CCA GGA GAT
GAG GCA GAC GAG GAG GAC G-3'
```

The mutated site is underlined. Mutant and wild-type (WT) Na_v1.5 channels in a pcDNA1 construct were purified using Qiagen columns (Qiagen Inc., Chatsworth, CA, USA).

2.4. TsA201 cell line transfection

The tsA201 cell line is a mammalian cell line derived from human embryonic kidney HEK 293 cells by stable transfection with SV40 large T antigen [17]. The tsA201 cells were grown and transfected using the calcium phosphate method as already described [17] with the following modification to facilitate the identification of individual transfected cells: a co-transfection with an expression plasmid for a lymphocyte surface antigen (CD8-a) was performed [18]. The human Na⁺ channel β_1 -subunit and CD8 were constructed in the piRES vector (piERS/CD8/ β_1). Using this strategy, transfected cells that bind beads (Dynal A.S., Oslo, Norway) also express the β_1 -subunit and are visually distinguishable from nontransfected cells by light microscopy.

2.5. Patch clamp method

Macroscopic Na⁺ currents from tsA201-transfected cells were recorded using the whole-cell configuration of the patch clamp technique [19]. Patch electrodes were made from 8161 Corning borosilicate glass and coated with Sylgard (Dow-Corning, Midland, MI, USA) to minimize their capacitance. Patch clamp recordings were made using low resistance electrodes (<1 M Ω), and a routine series resistance compensation by an Axopatch 200 amplifier (Axon Instruments, Foster City, CA, USA) was performed to values >80% to minimize voltage-clamp errors. Voltage-clamp command pulses were generated by microcomputer using pCLAMP software v8.0 (Axon Instruments). Na⁺ currents were filtered at 5 kHz, digitized at 10 kHz and stored on a microcomputer equipped with an AD converter (Digidata 1300, Axon Instruments). Data analysis was




Fig. 1. (A) 12-lead ECG during fever 39.2°C, showing coved ST segment elevation in the right precordial leads. (B) Fast non-sustained ventricular tachycardia during fever at a temperature of 39.2°C (indicated by arrow). (C) Normal 12-lead ECG in the absence of fever.

performed using a combination of pCLAMP software v9.0 (Axon Instruments), Microsoft Excel, and SigmaPlot 2001 for Windows version 7.0 (SPSS Inc., Chicago, IL, USA).

For temperature studies, the bath solution was heated using a bipolar temperature controller (Model: TC-202) from Medical systems Corp., Greenvale, N.Y. USA. The temperature was measured as close as possible to the cell using a Barnant thermistor thermometer.

2.6. Solutions and reagents

For whole-cell recordings, the patch pipette contained 35mM NaCl, 105mM CsF, 10mM EGTA, and 10mM Cs-HEPES. The pH was adjusted to 7.4 using 1N CsOH. The bath solution contained 150mM NaCl, 2mM KCl, 1.5mM CaCl₂, 1mM MgCl₂, 10mM glucose, and 10mM Na-HEPES. The pH was adjusted to 7.4 with 1N NaOH. A




Fig. 2. (A) Sequencing revealed a T to C base change in exon 23 of *SCN5A* gene in the patient compared to the control, resulting in the F1344S mutation at the heterozygous state. (B) Family pedigree. Index patient II-1 shows the BS phenotype and is carrier of the F1344S *SCN5A* mutation (black filled square). Three of the four daughters are carriers of the mutation, their baseline ECGs are normal, flecainide testing to unmask the BS phenotype was not performed (semi black circles, indicating a positive genotype but negative phenotype). Four brothers of the index patient II-1 died suddenly.

–7 mV correction of the liquid junction potential between the patch pipette and the bath solutions was performed. The recordings were made ten minutes after obtaining the whole-cell configuration in order to allow the current to stabilize and achieve adequate diffusion of the contents of the patch electrode and minimize the shift of gating observed under these conditions [20]. Experiments were carried out at either room temperature (22–23 °C) or at 40.5 °C to simulate fever.

2.7. Statistical analysis

Data are expressed as means \pm S.E.M. (standard error of the mean). Where indicated, a *t*-test was performed using statistical software in SigmaPlot (Jandel Scientific Software, San Rafael, CA, USA). Differences were considered significant when the *P* value was <0.05.

3. Results

3.1. Brugada syndrome phenotype during fever

The index patient II-1, a 42-year-old construction worker, presented to the emergency room with fever 39.2 °C, cough and pleuritic pain. Before his admission to the hospital, he had taken paracetamol and phenylephrin p.o., but no other drugs, particularly no antidepressants or other QT-interval prolonging medications. Diagnosis of pneumonia was made in the hospital. His 12-lead ECG recorded during high fever (39.2 °C) showed the characteristic Brugada type 1-changes [21] with coved-type ST segment elevations in V1–V2 (Fig. 1A). Polymorphic non-sustained VT were registered (Fig. 1B), and the patient received atenolol 12.5 mg p.o. and magnesium i.v. Twenty-five minutes later, he developed VF requiring two defibrillations. Under antipyretic therapy, repolarization normalized in the right precordial leads and there were no further ventricular arrhythmias (Fig. 1C). Antibiotic therapy with piperacillin/tazobactam was initiated




Fig. 4. (A) The mean current–voltage (*I/V*) relationships expressed as current density, where the amplitude of Na^+ currents were normalized to the cell capacitance and plotted versus the applied voltage. Similar protocol used as shown in Fig. 1, were used here (see inset); **P*<0.05 and ***P*<0.01. (B) The voltage dependence of steady-state activation (*G/V*) of $\text{Na}_v1.5/\text{WT}$ compared to the one obtained from $\text{Na}_v1.5/\text{F1344S}$, constructed from the *I/V* shown on panel (A). The data points of the *G/V* curve were fitted using a Boltzmann equation with $V_{1/2}$ and K_v representing, respectively, the slope factor and the half-maximum voltage of activation: $I/I_{\text{max}} = 1/(1 + \exp((V - V_{1/2})/K_v))$, I_{max} represents the maximum current.

after resuscitation. A flecainide challenge unmasked the BS type 1 phenotype (ECG not shown). After treatment of his pneumonia, a cardioverter-defibrillator (ICD) was implanted. ICD interrogation during a 28-month follow-up showed no episodes of VT/VF.




Fig. 3. The family of whole-cell sodium current traces from (A) $\text{Na}_v1.5/\text{WT}$ and from (B) $\text{Na}_v1.5/\text{F1344S}$ expressed in the tsA201 cell line. Currents were generated from a holding potential of –140 mV from –80 to +50 mV during 50 ms in 10-mV increments as shown in inset.

3.2. Identification of the F1344S mutation in SCN5A and family screening

We identified a novel missense mutation, F1344S, in SCN5A in the index patient II-1 by direct DNA sequencing (Fig. 2A). A heterozygous T to C base change at position 4031 in exon 23 resulted in the change of Phenylalanine (TTC) to Serine (TCC) in residue 1344. The mutation was located in the DIII-S5 transmembrane region of the Na_v1.5 sodium channel, a region highly conserved in many Na channels from different species (data not shown). In the index patient, we found the following common polymorphisms in SCN5A (all at the homozygous state): C280C (T840C), R552G (C1654G), Q1027R (A3080G) and D1819D (C5457T). The H558R polymorphism, which is supposed to modulate the biophysical properties and the trafficking of SCN5A in the presence of other mutations, was absent in our patient [22,23].

The four daughters of the patient were screened clinically and genetically (Fig. 2B). Subject III-1 is a 15-year-old girl with a normal baseline ECG and normal echocardiography. She suffers from recurrent syncope occurring several times per year usually after getting up in the morning or related to periods of sleep deprivation. She never had a syncope during fever. Genetic testing revealed the F1344S mutation. Subject III-2 is a 12-year-old girl without history of syncope, with normal ECG and normal echocardiography. She does not carry the F1344S mutation. Subject III-3 is a 9-year-old girl with a history of one syncope during school class, and with normal ECG and echocardiography. She is also a carrier of the F1344S mutation. The fourth child is a 4-year-old girl (III-4) who never had syncope and has normal ECG. She also carries the mutation. Unfortunately, the parents declined flecainide testing in the children carrying the mutation. Family history revealed that four

brothers of the index patient died between the age of 6 months and 3 years. The cause of death is not clear as the family lives abroad. The mother of the index patient died from lung disease; the father lives abroad and could not be tested.

3.3. Biophysical characteristics of Na_v1.5/F1344S mutant Na⁺ channels

3.3.1. Macroscopic Na_v1.5 recordings and current densities

Macroscopic Na⁺ currents were recorded first at room temperature from tsA201 cells expressing either WT (Na_v1.5/WT) or mutant channels (Na_v1.5/F1344S) co-transfected with the β₁-subunit. The resulting Na_v1.5/WT and Na_v1.5/F1344S Na⁺ currents showed fast activation and inactivation kinetics (Fig. 3). Current densities in pA/pF for the WT and Na_v1.5/F1344S mutant channels measured from cells that were transfected with equal amount of DNA were not statistically different (Fig. 4A). However, the potential at which Na current appears was shifted to more positive potentials. This resulted in a shift of the *G/V* curve (steady-state activation) of about 10 mV to more positive potentials with no statistical changes in the slope factor for F1344S mutation (see Table 1 for parameters).

Steady-state inactivation was also studied using a double pulse protocol (Fig. 5A). No significant shifts in either half inactivation (*V*_{1/2}) or slope factor were observed on mutant channels compared to the WT channels. The recovery from inactivation studied at –120 mV using a two-pulse protocol shows a rapid recovery (Fig. 5B) (see Table 1 for parameters).

Entry to slow inactivation was shown to be affected in BS mutant channels, however, the slow inactivation of Na_v1.5/F1344S mutation was not statistically significant from WT (Fig. 6A).

Table 1
Biophysical parameters of Na_v1.5/WT and Na_v1.5/F1344S

	23 °C		40.5 °C	
	Na _v 1.5/WT	Na _v 1.5/F1344S	Na _v 1.5/WT	Na _v 1.5/F1344S
<i>Steady-state activation</i>				
<i>V</i> _{1/2} (mV)	–60.16 ± 1.42 (<i>n</i> = 10)	–50.43 ± 2.03** (<i>n</i> = 9)	–60.69 ± 2.60 (<i>n</i> = 9)	–42.44 ± 2.7** (<i>n</i> = 5)
<i>K</i> _v (mV)	–6.33 ± 0.33 (<i>n</i> = 10)	–6.99 ± 0.52 (<i>n</i> = 9)	–6.49 ± 0.67 (<i>n</i> = 9)	–10.27 ± 0.80** (<i>n</i> = 5)
<i>Steady-state inactivation</i>				
<i>V</i> _{1/2} (mV)	–103.82 ± 0.64 (<i>n</i> = 8)	–104.47 ± 0.93 (<i>n</i> = 9)		
<i>K</i> _v (mV)	5.61 ± 0.07 (<i>n</i> = 8)	4.65 ± 0.06 (<i>n</i> = 9)		
<i>Slow inactivation</i>				
τ (ms)	251.25 ± 32.37 (<i>n</i> = 8)	220.11 ± 29.89 (<i>n</i> = 9)		
<i>Recovery from inactivation</i>				
τ (ms)	22.43 ± 1.60 (<i>n</i> = 8)	17.60 ± 1.88* (<i>n</i> = 9)		

*V*_{1/2} = Mid point for activation or inactivation.

*K*_v = slope factor.

τ = time constant.

* *P* < 0.05.

** *P* < 0.01.




Fig. 5. (A) Steady-state availability curve was determined by using 500 ms conditioning pulses to voltages between -140 and -30 mV to a standard test pulse to either -30 mV (see inset). Test currents were normalized and plotted versus conditioning voltage. (B) Recovery from fast inactivation obtained using a double pulse protocol (see inset). A standard test pulse was used to monitor recovery, and the normalized test currents were plotted versus the recovery interval.

The frequency-dependent effect of Na^+ current amplitudes was studied at frequencies found during fever in comparison with a normal frequency of stimulation. As expected since the recovery from inactivation was faster in the presence of the mutation, the currents were larger at higher frequency of stimulation, exhibiting a resistant to block (Figs. 6B and 7).

3.3.2. Effect of temperature on channel properties

When macroscopic Na^+ currents were recorded at temperatures up to 40.5°C , no effect was seen on mutant $\text{Na}_v1.5/\text{F1344S}$ channels compared to WT channels (Fig. 8, upper panel).

As expected, rising the temperature from 22 to 40.5°C markedly increased the rate of inactivation for WT and F1344S mutant channels (Fig. 8B and C). There was also no effect on activation of WT channels at 23°C and 40.5°C (parameters not shown). In contrast activation curves showed an 8 mV shift of activation towards more positive

potential with a significant change in the slope factor for mutant $\text{Na}_v1.5/\text{F1344S}$ channels measured at 40.5°C versus 23°C (Fig. 8D). Indeed, changes in temperature resulted in a further shift of the voltage-dependent activation curves towards more positive voltages with a significant effect on the slope factor (Fig. 8D) for F1344S mutation at 40.5°C (see Table 1 for parameters). Although the figure shows a slight increase in current amplitudes, the maximum current densities at 40.5°C were not statistically significant from the one recorded at room temperature (data not shown).

4. Discussion

It is well recognized that the ECG patterns of ST segment elevation in the right precordial leads in patients with BS are inconstant and can be revealed by external factors such as medication and fever [14,24–26]. Although the effect of drugs such as class I antiarrhythmic's, cocaine and antidepressant is probably related to the blockade of sodium channels, the molecular and the ionic mechanisms related to the effect of fever remain elusive.

We report a novel *SCN5A* mutation, F1344S, in a family with BS phenotype, associated in the index patient with fever-triggered VF. This mutation results in a loss of Na^+ channel function by shifting the steady-state activation towards more positive potentials. The analysis of the mutant channels in heterologous expression system (tsA201 cell line) reveals normal kinetics of inactivation but a shift in activation that could potentially reduce the availability of sodium channels. A shift of the activation curve was found to underlay several BS mutations [27]. As the index patient developed the BS phenotype only during fever we studied the effect of the mutant $\text{Na}_v1.5/\text{F1344S}$ channel properties at different temperatures. Activation curves showed the 10 mV shift of activation towards more positive potential at 40.5°C as noted at normal baseline experimental temperature of 23°C . Interestingly, in addition to the shift of activation, we found a significant change in the slope factor. The slope was less steep for mutant $\text{Na}_v1.5/\text{F1344S}$ channels at 40.5°C compared to the one measured at 23°C . Apart from the BS, fever was identified as a precipitant of idiopathic VF in a series of patients with structurally normal hearts [28]. In the study of Pasquie et al. temperature-dependent modification of ion channel properties or expression were proposed to facilitate spontaneous activity within the right ventricular outflow tract or the Purkinje system as a potential mechanism to initiate VF.

In the present study, for the first time we show that the effect of temperature can be related to a further shift in activation with a reduced slope factor, suggesting that the activation energies are markedly reduced in the presence of this specific mutation. Moreover, the F to S mutation may have a large effect on the structure of channel proteins since F is completely hydrophobic and S it may H-bond with neighboring amino acid residues because of the presence of an OH group.




Fig. 6. (A) Development of slow inactivation of $\text{Na}_v1.5/\text{WT}$ and $\text{Na}_v1.5/\text{F1344S}$ sodium channels. Time course of entry into the slow inactivated state was measured by using a triple-pulse protocol consisting of a variable duration conditioning pulse (2 ms to 1 s) to -30mV to inactivate the channels. A 20-ms interpulse to -140mV was applied to promote the rapid recovery of inactivated channels, and a standard test pulse was used to assay availability (see inset). The test currents were normalized and plotted versus the conditioning pulse interval ($\text{Na}_v1.5/\text{WT}$, \blacksquare ; $\text{Na}_v1.5/\text{F1344S}$, \bullet). (B) Frequency-dependent inhibition of $\text{Na}_v1.5/\text{WT}$ and $\text{Na}_v1.5/\text{F1344S}$ sodium currents. A train of 50 pulses was applied to -10mV ($\text{Na}_v1.5$; $n=9$) or -10mV ($\text{Na}_v1.5/\text{F1344S}$; $n=11$) at frequencies between 5 and 50 Hz. The peak currents elicited by each test pulse were normalized to the current of the first pulse (P_n/P_1 , where $n=1-50$) and were plotted versus the pulse number (see inset). The pulse duration was 8 ms. The holding and interpulse potentials were -120mV .

Fever is usually associated with sinus tachycardia, which is a confounding factor. Indeed, the index patient had a heart rate of 103 bpm. Therefore, we studied the effect of varying the frequency of stimulation on Na^+ current amplitudes. In contrast to WT channels, Na currents show even a resistant to block at high frequency of stimulation, probably due to

the fast recovery from inactivation. We found that the currents were increased at higher frequency of stimulation. Thus, a raise in heart rate seems not to be contributing to the risk for developing VT in patients carrying this particular mutation. This apparent gain of function will not result in a rescue of the loss of function due to the shift of activation.




Fig. 7. (A) Ratio of the currents elicited by the 50th and first pulses (P_{50}/P_1) versus the pulsing frequency. (B and C) Representative raw current traces of $\text{Na}_v1.5/\text{WT}$ (B) and $\text{Na}_v1.5/\text{F1344S}$ (C) stimulated at 20 Hz.




Fig. 8. Effect of temperature on $\text{Na}_v1.5/\text{WT}$ and $\text{Na}_v1.5/\text{F1344S}$ current and G/V curves. No differences in macroscopic Na^+ currents recordings for WT and mutant currents at 40.5°C temperature (B–C). (D) Further shift of activation curves toward more positive voltages with a significant ($*P < 0.05$) effect on the slope factor in mutant currents at 40.5°C . The data point of the G/V curve were fitted using a Boltzmann equation.

The F1344S mutation segregated to three of the four daughters. Four brothers of the index patient died suddenly at a very young age. It is possible that they were carriers of the F1344S mutation, suggesting a malignant course. Unfortunately no data on their phenotypes are available.

Several antibiotics and antidepressants such as tricyclic antidepressants are known to induce torsades de pointes by QT-interval prolongation or BS, respectively. One could speculate that the antibiotic agent may have influenced the repolarization of the mutant channels. Piperacillin/tazobactam is not known to prolong the QT-interval (www.torsades.org) and we do not further followed this hypothesis, also because the drug was administered after the initiation of VF. Before hospital admission, the patient took phenylephrin p.o. It is not known whether phenylephrin has the potential to unmask the BS phenotype and might have contributed to trigger VF.

In this patient and in his daughters carrying the F1344S *SCN5A* mutation, future episodes of fever should be aggressively treated with antipyretic agents whereas beta-blockers and phenylephrin should be completely avoided.

5. Conclusion

We identified a novel mutation in *SCN5A*, F1344S, in a patient with the BS and fever-induced VF. In our in vitro model we found that the mutation resulted in a loss of sodium channel function, as previously described for other *SCN5A* mutations leading to the BS. For the F1344S mutation, the mechanism was most probably a loss of function due to the shift of activation. Temperature

simulating fever resulted in a further shift of activation and a reduction in the slope factor. Taken together, our findings indicate that the shift in activation and change in the slope factor at higher temperature mimicking fever could reduce sodium currents availability and trigger the manifestation of the BS phenotype. Fever should be vigorously treated with antipyretics in patients with fever-induced BS.

Acknowledgements

We are grateful to Dr. Véronique Fressart and Dr. Pascale Guichenev, INSERM U582 in Paris, France, for the verification of the mutation.

Dr. D.I. Keller was supported by grants from the University Hospital Basel, Switzerland, grants from the Swiss Electrophysiology/Pacemaker Foundation and the L. and Th. La Roche Foundation, Switzerland. The study was supported by the “Fondation Leducq” and grants from the Heart and Stroke Foundation of Québec (HSFQ), the Canadian Institutes of Health Research (CIHR) MT-13181. Dr. M. Chahine is an Edwards Senior Investigator (Joseph C. Edwards Foundation).

References

- [1] Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. *J Am Coll Cardiol* 1992;20:1391–6.
- [2] Miyazaki T, Mitamura H, Miyoshi S, Soejima K, Aizawa Y, Ogawa S. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. *J Am Coll Cardiol* 1996;27:1061–70.

- [3] Brugada R, Brugada J, Antzelevitch C, Kirsch GE, Potenza D, Towbin JA, et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. *Circulation* 2000;101:510–5.
- [4] Rolf S, Bruns HJ, Wichter T, Kirchhof P, Ribbing M, Wasmer K, et al. The ajmaline challenge in Brugada syndrome: diagnostic impact, safety, and recommended protocol. *Eur Heart J* 2003;24:1104–12.
- [5] Wilde AAM, Antzelevitch C, Borggrefe M, Brugada J, Brugada R, Brugada P, et al. Proposed diagnostic criteria for the Brugada syndrome: consensus report. *Circulation* 2002;106:2514–9.
- [6] Weiss R, Barmada MM, Nguyen T, Seibel JS, Cavlovich D, Kornblit CA, et al. Clinical and molecular heterogeneity in the Brugada syndrome: a novel gene locus on chromosome 3. *Circulation* 2002;105:707–13.
- [7] Antzelevitch C. The Brugada syndrome. *J Cardiovasc Electrophysiol* 1998;9:513–6.
- [8] Gussak I, Antzelevitch C, Bjerregaard P, Towbin JA, Chaitman BR. The Brugada syndrome: clinical, electrophysiologic and genetic aspects. *J Am Coll Cardiol* 1999;33:5–15.
- [9] Baroudi G, Pouliot V, Denjoy I, Guicheney P, Shrier A, Chahine M. Novel mechanism for Brugada syndrome: defective surface localization of an *SCN5A* mutant (R1432G). *Circ Res* 2001;88:E78–83.
- [10] Baroudi G, Acharfi S, Larouche C, Chahine M. Expression and intracellular localization of an *SCN5A* double mutant R1232W/T1620M implicated in Brugada syndrome. *Circ Res* 2002;90:E11–6.
- [11] Baroudi G, Napolitano C, Priori SG, Del Bufalo A, Chahine M. Loss of function associated with novel mutations of the *SCN5A* gene in patients with Brugada syndrome. *Can J Cardiol* 2004;20:425–30.
- [12] Antzelevitch C, Brugada R. Fever and Brugada syndrome. *Pacing Clin Electrophysiol* 2002;25:1537–9.
- [13] Saura D, Garcia-Alberola A, Carrillo P, Pascual D, Martinez-Sanchez J, Valdes M. Brugada-like electrocardiographic pattern induced by fever. *Pacing Clin Electrophysiol* 2002;25:856–9.
- [14] Mok NS, Priori SG, Napolitano C, Chan NY, Chahine M, Baroudi G. A newly characterized *SCN5A* mutation underlying Brugada syndrome unmasked by hyperthermia. *J Cardiovasc Electrophysiol* 2003;14:407–11.
- [15] Keller DI, Rougier JS, Kucera JP, Benammar N, Fressart V, Guicheney P, et al. Brugada syndrome and fever: genetic and molecular characterization of patients carrying *SCN5A* mutations. *Cardiovasc Res* 2005;67:510–9.
- [16] Wang Q, Li Z, Shen J, Keating MT. Genomic organization of the human *SCN5A* gene encoding the cardiac sodium channel. *Genomics* 1996;34:9–16.
- [17] Margolskee RF, McHendry-Rinde B, Horn R. Panning transfected cells for electrophysiological studies. *Biotechniques* 1993;15:906–11.
- [18] Jurman ME, Boland LM, Liu Y, Yellen G. Visual identification of individual transfected cells for electrophysiology using antibody-coated beads. *Biotechniques* 1994;17:876–81.
- [19] Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. *Pflugers Arch* 1981;391:85–100.
- [20] Wang DW, George Jr AL, Bennett PB. Comparison of heterologously expressed human cardiac and skeletal muscle sodium channels. *Biophys J* 1996;70:238–45.
- [21] Wilde AAM, Antzelevitch C, Borggrefe M, Brugada J, Brugada R, Brugada P, et al. Proposed diagnostic criteria for the Brugada syndrome. *Eur Heart J* 2002;23:1648–54.
- [22] Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC, et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. *Circulation* 2002;105:1943–8.
- [23] Makielski JC, Ye B, Valdivia CR, Pagel MD, Pu J, Tester DJ, et al. A ubiquitous splice variant and a common polymorphism affect heterologous expression of recombinant human *SCN5A* heart sodium channels. *Circ Res* 2003;93:821–8.
- [24] Darbar D, Yang T, Churchwell K, Wilde AA, Roden DM. Unmasking of Brugada syndrome by lithium. *Circulation* 2005;112:1527–31.
- [25] Bigwood B, Galler D, Amir N, Smith W. Brugada syndrome following tricyclic antidepressant overdose. *Anaesth Intensive Care* 2005;33:266–70.
- [26] Aouate P, Clerc J, Viard P, Seoud J. Propranolol intoxication revealing a Brugada syndrome. *J Cardiovasc Electrophysiol* 2005;16:348–51.
- [27] Smits JPP, Koopmann TT, Wilders R, Veldkamp MW, Opthof T, Bhuiyan ZA, et al. A mutation in the human cardiac sodium channel (E161K) contributes to sick sinus syndrome, conduction disease and Brugada syndrome in two families. *J Mol Cell Cardiol* 2005;38:969–81.
- [28] Pasquié JL, Sanders P, Hocini M, Hsu LF, Scavée C, Jais P, et al. Fever as a precipitant of idiopathic ventricular fibrillation in patients with normal hearts. *J Cardiovasc Electrophysiol* 2004;15:1271–6.